A Study of the Prevalence of Human Parvovirus B19 in Thalassemia Patients in the Al Najaf Governorate

The purpose of this study was to examine the incidence of human parvovirus B19 in thalassemia patients between August 2022 and January 2023 at the Al-Zahra teaching hospital in the Al-Najaf administration. The ages of the 70 thalassemia patients and the 35 normal (parentally healthy) cases included as a control group range from 5 to 64 years. B19 is a newly discovered agent that can spread through blood transfusions. Patients with thalassemia are at risk for B19 infection since they undergo a high transfusion regimen; B19 is resistant to viral inactivation treatments; and donor units are not checked for B19; nonetheless, there have been very few research conducted on this topic, and none in Asia. Therefore, researchers set out to examine the spread of B19 infection among multi-transfused thalassemia patients.